The tumor signal intensity after ZEGFR:03115–IR700DX injection (6 μg) was calculated to be >6‐fold higher than the signal measured for ZTaq‐IR700DX, which confirmed the EGFR specificity of the affibody‐based conjugate in vivo (Figs. 4a and 4c). This evidence concerns the gene EGFR and neoplasm.